Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference

Core Viewpoint - Pelthos Therapeutics Inc. is actively participating in the Wells Fargo Healthcare Conference, showcasing its commitment to addressing unmet patient needs through innovative therapeutic products [1][2]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing safe and effective therapeutic products for patients with unmet treatment burdens [3]. - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, received FDA approval in 2024 for the treatment of molluscum contagiosum [3]. Event Details - The management presentation at the Wells Fargo Healthcare Conference is scheduled for September 3, 2025, at 1:30 p.m. E.T. [1]. - A webcast of the presentation will be available on Pelthos' website, with archived replays accessible for 90 days post-event [2].